| HOME >> BIOLOGY >> TECHNOLOGY |
[20] Based on Evaluate Pharma estimates for 2016.
[21] Sourced from the Biogen presentation made to investors on February 6, 2013 which states on slide 13 that "Asset Purchase Structure Enables: Approximately US$30M in annual operating synergies relatively seamlessly"
[22] The closing share price of Elan ADS's on the New York Stock Exchange on February 15, 2013.
[23] Sourced from Elan's Total Voting Rights announcement filed on January 31, 2013 and adjusted for restricted stock units vested between that date and the date of the Proposal Announcement.
[24] Dilutive impact calculation based on the treasury share method.
[25] Per Alkermes plc (ALKS) 13-D SEC filing on February 6, 2013.
[26] Elan's remaining funding commitment to Janssen AI as at February 2013 plus the amount provided in January 2013, as disclosed in Elan's 20-F SEC filing on February 12, 2013.
[27] Extracted from Elan's 20-F SEC filing on February 12, 2013 for the financial year ended December 31, 2012.
[28] Extracted from Elan's 20-F SEC filing on February 12, 2013 for the financial year ended December 31, 2012.
[29] Calculated as the closing share price of Prothena's ordinary shares of US$6.01 on the NASDAQ Stock Market on February 15, 2013 times 3,182,253 ordinary shares owned by Elan as disclosed in Elan's Form 3 SEC filing on December 20, 2012.
[30] Expected cash upfront payment by Biogen to the Elan Group on closing of the Tysabri Transaction which was announced by Biogen on February 6, 2013.
| SOURCE RP Management, LLC Copyright©2012 PR Newswire. All rights reserved |